Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.39 |
| ▸ | RELA | Q04206 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052576 | 1.00 | MAPK1 (0.41) | MAPK1NFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL8578253 | 0.83 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| SCHEMBL8577970 | 0.77 | NFKB1 (0.46) | MAPK1NFKB1NFKB2RELA | |
| SCHEMBL7051372 | 0.69 | ALDH1A1 (0.44) | MAPK1ALDH1A1ALOX15CYP2C19HIF1A | |
| SCHEMBL7051771 | 0.69 | ALDH1A1 (0.44) | MAPK1ALDH1A1ALOX15CYP2C19HIF1A | |
| SCHEMBL7050025 | 0.69 | ALDH1A1 (0.44) | MAPK1ALDH1A1ALOX15CYP2C19HIF1A | |
| SCHEMBL7051369 | 0.69 | ALDH1A1 (0.44) | MAPK1ALDH1A1ALOX15CYP2C19HIF1A | |
| SCHEMBL7051770 | 0.69 | ALDH1A1 (0.44) | MAPK1ALDH1A1ALOX15CYP2C19HIF1A | |
| SCHEMBL7047885 | 0.68 | ALDH1A1 (0.40) | MAPK1ALDH1A1ALOX15MAPTKMT2A | |
| SCHEMBL7047888 | 0.68 | ALDH1A1 (0.40) | MAPK1ALDH1A1ALOX15MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281797-A1 | KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF | SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) | 2022-09-08 | — | — | US | disclosed |
| WO-2022057734-A1 | KEY INTERMEDIATE FOR SYNTHESIZING PROSTAGLANDIN COMPOUNDS AND PREPARATION METHOD THEREFOR | 凯特立斯（深圳）科技有限公司 | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281797-A1 | KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF | PTGES, PTGIS, PTGES2 | MAPK1 1820/4885NFKB1 517/4885NFKB2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.